H. Lundbeck A/S: Epilepsy trials

The registry lists 11 Epilepsy studies with H. Lundbeck A/S as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 3Phase 2 3Phase 3 5No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)Enrolling by invitationNCT06908226Phase 3
• Intermediate-Size Expanded Access Protocol (EAP) for LP352AvailableNCT06149663
• Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With EpilepsyCompletedNCT01128959Phase 3Results posted
• Clobazam in Patients With Lennox-Gastaut SyndromeCompletedNCT00518713Phase 3Results posted
• Clobazam in Subjects With Lennox-Gastaut SyndromeCompletedNCT00162981Phase 2Results posted
• A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)Active, not recruitingNCT06719141Phase 3
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Active, not recruitingNCT06660394Phase 3
• Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic EncephalopathyCompletedNCT05626634Phase 2
• Study to Investigate LP352 in Subjects With Developmental and Epileptic EncephalopathiesCompletedNCT05364021Phase 1/2
• A Study of Lu AG06466 in Participants With Treatment Resistant Focal EpilepsyTerminatedNCT05081518Phase 1
• A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With EpilepsyCompletedNCT01079351Phase 1